S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
All the trading advice you’ve ever received boils down to this (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
All the trading advice you’ve ever received boils down to this (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
All the trading advice you’ve ever received boils down to this (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
All the trading advice you’ve ever received boils down to this (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
All the trading advice you’ve ever received boils down to this (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
All the trading advice you’ve ever received boils down to this (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
All the trading advice you’ve ever received boils down to this (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
All the trading advice you’ve ever received boils down to this (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
All the trading advice you’ve ever received boils down to this (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
All the trading advice you’ve ever received boils down to this (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
All the trading advice you’ve ever received boils down to this (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
All the trading advice you’ve ever received boils down to this (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?

Illumina Stock Price, News & Analysis (NASDAQ:ILMN)

$113.99
+2.23 (+2.00%)
(As of 12/6/2023 ET)
Compare
Today's Range
$111.92
▼
$117.79
50-Day Range
$92.79
▼
$140.02
52-Week Range
$89.00
▼
$238.55
Volume
1.96 million shs
Average Volume
1.68 million shs
Market Capitalization
$18.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$194.56
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Illumina MarketRank™ Stock Analysis

Analyst Rating
Hold
2.24 Rating Score
Upside/​Downside
70.7% Upside
$194.56 Price Target
Short Interest
Healthy
3.41% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
0.63mentions of Illumina in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$35,545 Sold Last Quarter
Proj. Earnings Growth
55.88%
From $0.68 to $1.06 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.90 out of 5 stars

Medical Sector

35th out of 957 stocks

Analytical Instruments Industry

1st out of 24 stocks

See Top Rated MarketRank™ Stocks Here

ILMN stock logo

About Illumina Stock (NASDAQ:ILMN)

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. Further, it provides whole-genome sequencing, genotyping, NIPT, and product support services; and Galleri, a multi-cancer early detection test. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Further, it markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

ILMN Stock Price History

ILMN Stock News Headlines

December 7, 2023 | americanbankingnews.com
Q3 2025 Earnings Forecast for Illumina, Inc. Issued By Leerink Partnrs (NASDAQ:ILMN)
December 6, 2023 | benzinga.com
Illumina Options Trading: A Deep Dive into Market Sentiment
December 7, 2023 | DTI Trader (Ad)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
December 6, 2023 | markets.businessinsider.com
Kessler Topaz Meltzer & Check, LLP Notifies Illumina, Inc. Investors of Securities Fraud Class Action Lawsuit Filed on Their Behalf
December 6, 2023 | americanbankingnews.com
Research Analysts Offer Predictions for Illumina, Inc.'s Q1 2025 Earnings (NASDAQ:ILMN)
December 4, 2023 | benzinga.com
Investors Sue Illumina (ILMN) for Concealing Facts Concerning GRAIL Acquisition – Hagens Berman
December 1, 2023 | msn.com
Illumina says there is outside interest in buying Grail
December 1, 2023 | benzinga.com
DEADLINE ALERT for PAYC, ILMN, and JRVR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
December 7, 2023 | DTI Trader (Ad)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
December 1, 2023 | barrons.com
INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Illumina, Inc. (ILMN) of a Class Action Lawsuit and an Upcoming Deadline
November 30, 2023 | businesswire.com
ILMN Shareholders Upcoming Deadline: Bronstein, Gewirtz & Grossman LLC Reminds Investors of The Illumina, Inc. to Contact the Firm
November 30, 2023 | finance.yahoo.com
Video: Merging Discovery With Clinical Care at Ontario Institute for Cancer Research
November 29, 2023 | seekingalpha.com
Illumina, Inc. (ILMN) Piper Sandler 35th Annual Healthcare Conference (Transcript)
November 29, 2023 | ca.finance.yahoo.com
Factbox-US Supreme Court case on SEC could have wide impact on agency enforcement
November 29, 2023 | businesswire.com
ILMN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Illumina, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
November 28, 2023 | stockhouse.com
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Illumina, Inc. (ILMN) of a Class Action Lawsuit and an Upcoming Deadline
November 28, 2023 | msn.com
Illumina has been contacted by parties interested in Grail: report
November 28, 2023 | seekingalpha.com
Illumina, Inc. (ILMN) Evercore ISI 6th Annual HealthCONx Conference
November 26, 2023 | markets.businessinsider.com
INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Illumina, Inc. (ILMN) of a Class Action Lawsuit and an Upcoming Deadline
November 25, 2023 | money.usnews.com
Illumina Inc
November 25, 2023 | benzinga.com
ILMN Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Illumina, Inc. (ILMN) Investors of Securities Fraud Class Action Lawsuit
November 24, 2023 | barrons.com
INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Illumina, Inc. with Losses of $100,000 to Contact the Firm
November 24, 2023 | markets.businessinsider.com
INVESTOR ALERT: Levi & Korsinsky Notifies Illumina, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – ILMN
November 23, 2023 | barrons.com
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Illumina, Inc. with Losses of $100,000 to Contact the Firm
November 21, 2023 | markets.businessinsider.com
Illumina Shareholder Action Reminder
November 20, 2023 | markets.businessinsider.com
Illumina Notice: Kessler Topaz Meltzer & Check, LLP Notifies Investors of Securities Fraud Class Action Lawsuit Filed against Illumina, Inc. (ILMN)
November 20, 2023 | benzinga.com
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Illumina, Inc. (ILMN) Investors of a Class Action Lawsuit and Upcoming Deadline
See More Headlines
Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/07/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/06/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:ILMN
CUSIP
45232710
CIK
1110803
Web
www.illumina.com
Phone
(858) 202-4500
Fax
858-202-4766
Employees
10,260
Year Founded
1998

Price Target and Rating

Average Stock Price Target
$194.56
High Stock Price Target
$328.00
Low Stock Price Target
$100.00
Potential Upside/Downside
+70.7%
Consensus Rating
Hold
Rating Score (0-4)
2.24
Research Coverage
17 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($7.12)
Trailing P/E Ratio
N/A
Forward P/E Ratio
167.63
P/E Growth
7.3
Net Income
$-4,404,000,000.00
Net Margins
-25.20%
Pretax Margin
-24.99%
Return on Equity
2.13%
Return on Assets
1.19%

Debt

Debt-to-Equity Ratio
0.25
Current Ratio
1.69
Quick Ratio
1.28

Sales & Book Value

Annual Sales
$4.58 billion
Price / Sales
3.95
Cash Flow
$4.82 per share
Price / Cash Flow
23.66
Book Value
$41.95 per share
Price / Book
2.72

Miscellaneous

Outstanding Shares
158,800,000
Free Float
158,594,000
Market Cap
$18.10 billion
Optionable
Optionable
Beta
1.09

Social Links

10 Best Cheap Stocks to Buy Now Cover
10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Joydeep Goswami M.B.A. (Age 52)
    Ph.D., CFO, Chief Strategy & Corporate Development Officer
    Comp: $787.3k
  • Ms. Susan H. TousiMs. Susan H. Tousi (Age 54)
    Chief Commercial Officer
    Comp: $790.2k
  • Mr. Jacob Thaysen Ph.D. (Age 48)
    CEO & Director
  • Stephanie Campos
    President
  • Mr. Kevin Carl Pegels (Age 56)
    Chief of Global Operations
  • Mr. Scott Ericksen (Age 51)
    VP & Chief Accounting Officer
  • Dr. Steven Barnard Ph.D.
    Chief Technology Officer
  • Ms. Carissa L. Rollins (Age 53)
    Chief Information Officer
  • Ms. Sallilyn Schwartz
    Vice President of Investor Relations
  • Mr. Charles E. Dadswell Esq. (Age 64)
    Senior VP & General Counsel
    Comp: $1.06M

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

Should I Buy Illumina Stock? ILMN Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Illumina was last updated on Tuesday, November 28, 2023 at 10:32 PM.

Pros

Here are some ways that investors could benefit from investing in Illumina, Inc.:

  • Illumina specializes in DNA sequencing, a rapidly growing field in medical research. This technology has the potential to revolutionize healthcare by enabling personalized medicine and advancing the understanding of genetic diseases.
  • Illumina has a strong track record of innovation and product development. They continuously introduce new and improved sequencing platforms, such as the latest NovaSeq system, which offers high throughput and cost-effective sequencing.
  • The forced divestiture of Grail, a healthcare company focused on early cancer detection, could potentially increase shareholder value. If regulators require Illumina to spin off Grail, it could unlock additional value for investors.
  • Illumina has a global presence and serves customers in over 130 countries. This diversification helps mitigate risks associated with regional economic fluctuations and regulatory changes.
  • The current stock price of Illumina provides an attractive entry point for investors looking to capitalize on the long-term growth potential of the company. Please note that the stock price is subject to market fluctuations and investors should conduct their own research and analysis.

Cons

Investors should be bearish about investing in Illumina, Inc. for these reasons:

  • Illumina is facing regulatory challenges, such as the Federal Trade Commission's order to divest Grail. These regulatory hurdles could potentially impact the company's operations and financial performance.
  • Illumina has experienced declining sales and earnings in recent quarters. This trend raises concerns about the company's ability to generate sustainable revenue growth and profitability.
  • The ongoing legal battles and uncertainties surrounding the acquisition of Grail could create additional risks and uncertainties for Illumina and its investors.
  • Competition in the DNA sequencing market is intensifying, with the entry of new players and the development of alternative sequencing technologies. This increased competition could potentially impact Illumina's market share and pricing power.
  • Investing in Illumina involves risks associated with the healthcare industry, including regulatory changes, reimbursement challenges, and the need for continuous innovation to stay ahead of competitors.














ILMN Stock Analysis - Frequently Asked Questions

Should I buy or sell Illumina stock right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 3 sell ratings, 7 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View ILMN analyst ratings or view top-rated stocks.

What is Illumina's stock price target for 2024?

17 equities research analysts have issued 1 year price objectives for Illumina's shares. Their ILMN share price targets range from $100.00 to $328.00. On average, they anticipate the company's stock price to reach $194.56 in the next twelve months. This suggests a possible upside of 70.7% from the stock's current price.
View analysts price targets for ILMN or view top-rated stocks among Wall Street analysts.

How have ILMN shares performed in 2023?

Illumina's stock was trading at $202.20 on January 1st, 2023. Since then, ILMN shares have decreased by 43.6% and is now trading at $113.99.
View the best growth stocks for 2023 here.

When is Illumina's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 6th 2024.
View our ILMN earnings forecast.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) issued its earnings results on Thursday, November, 9th. The life sciences company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.20. The life sciences company earned $1.12 billion during the quarter, compared to analyst estimates of $1.13 billion. Illumina had a positive trailing twelve-month return on equity of 2.13% and a negative net margin of 25.20%. The business's revenue was up .4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.34 earnings per share.
Read the conference call transcript.

What ETFs hold Illumina's stock?

ETFs with the largest weight of Illumina (NASDAQ:ILMN) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Invesco Biotechnology & Genome ETF (PBE), VanEck Biotech ETF (BBH), Global X Telemedicine & Digital Health ETF (EDOC), First Trust NYSE Arca Biotechnology Index Fund (FBT), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ) and Global X Genomics & Biotechnology ETF (GNOM).

What guidance has Illumina issued on next quarter's earnings?

Illumina updated its FY 2023 earnings guidance on Thursday, November, 9th. The company provided earnings per share (EPS) guidance of $0.60-$0.70 for the period, compared to the consensus earnings per share estimate of $0.60. The company issued revenue guidance of $4.45 billion-$4.49 billion, compared to the consensus revenue estimate of $4.59 billion.

What is Francis deSouza's approval rating as Illumina's CEO?

496 employees have rated Illumina Chief Executive Officer Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among the company's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), Salesforce (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

Who are Illumina's major shareholders?

Illumina's stock is owned by a variety of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (6.61%), Polen Capital Management LLC (3.24%), Wellington Management Group LLP (3.13%), Loomis Sayles & Co. L P (2.53%), Bank of New York Mellon Corp (2.31%) and Morgan Stanley (2.25%). Insiders that own company stock include Aimee L Hoyt, Alexander Aravanis, Charles Dadswell, Francis A Desouza, Jay T Flatley, Mostafa Ronaghi, Phillip G Febbo, Susan H Tousi and Susan H Tousi.
View institutional ownership trends.

How do I buy shares of Illumina?

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Illumina have any subsidiaries?
The following companies are subsidiares of Illumina: Advanced Liquid Logic Inc., Affomix Corporation, BlueBee, BlueBee Belgium BVBA, BlueBee Holding BV, BlueGnome Ltd, BlueGnome Ltd., Conexio Genomics, Conexio Genomics Pty Ltd., Edico Genome, Emedgene Inc., Emedgene Technologies Ltd, Enancio, Enancio SAS, Epicentre Biotechnologies, GRAIL LLC, GenoLogics, Grail, Helixis, Illumina (China) Scientific Co Ltd, Illumina AB, Illumina Australia Pty. Ltd., Illumina Belgium BVBA, Illumina Brasil Produtos de Biotecnologia Ltda., Illumina Cambridge Ltd., Illumina Canada ULC, Illumina Denmark ApS, Illumina Finland Oy, Illumina France Sarl, Illumina GmbH, Illumina Hong Kong Limited, Illumina India Biotechnology Private Limited, Illumina Ireland Commercial Limited, Illumina Italy S.r.l., Illumina K.K. Japan, Illumina Korea Ltd., Illumina Netherlands B.V., Illumina New Zealand Limited, Illumina Norway AS, Illumina Productos de Espana S.L.U., Illumina Rus LLC, Illumina Shanghai (Trading) Co Ltd Beijing Branch, Illumina Shanghai (Trading) Co. Ltd., Illumina Singapore Pte. Ltd., Illumina Software Inc., Illumina Switzerland GmbH, Illumina US Manufacturing Operations Inc., Liquid Logic, Moleculo, NextBio, Solexa, Verinata Health, Verinata Health Inc., and thromboDx BV.
Read More
This page (NASDAQ:ILMN) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -